UnitedHealth shares rose 4% after beating Q3 2026 earnings estimates with adjusted EPS of $4.69 and raising its full-year outlook to at least $20.50. The earnings beat was driven by improved medical care ratio, helped partly by a $610 million reserve release, raising questions about sustainability. Its Optum Health unit rebounded strongly, offsetting a 10% revenue drop due to exiting some markets. However, UnitedHealth's medical membership fell from 50.1 million to 48.3 million, pressuring revenue despite beating estimates. Competitors Humana and Elevance Health also saw smaller gains. Investors will watch if the medical cost improvements hold once reserve benefits fade and how membership trends affect future revenue.
As of Oct 13, 2026 20:41 WIB, UnitedHealth trades at USD 385.00 on Pluang, recovering from its 52-week low of USD 259.02 but still below its 52-week high of USD 436.35. Humana is priced higher at USD 437.28, closer to its recent peak, while Elevance Health stands at USD 427.41. UnitedHealth's 1-day gain of 1.71% on Pluang outpaces Humana's 0.87% and Elevance's 1.26%, reflecting stronger buying interest with 64% buy orders compared to Humana's 44%.
UnitedHealth Group raised its 2026 earnings outlook following a 52% increase in third-quarter operating profit to $6.6 billion, driven by lower medical costs and better operational efficiency. The company now expects adjusted earnings of at least $20...
UnitedHealth Group reported Q3 earnings that exceeded expectations with EPS 13% above consensus, driven by a successful turnaround strategy focusing on shedding unprofitable patient groups and controlling costs. This led to a net margin increase from...
UnitedHealth Group reported third-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $4.69 versus the expected $4.14, and revenue of $112.69 billion. The company raised its fiscal 2026 adjusted earnings forecast ...
UnitedHealth Group is set to report earnings on October 13, with options showing implied volatility twice the realized volatility, making options expensive. This creates opportunities for traders to use short premium strategies, such as selling Novem...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
